newsfilter
← Latest News
GlobeNewswire·

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

JBIO
  • Jade Biosciences announced the first dosing of a participant in the Phase 2 JUNIPER trial evaluating JADE101 for immunoglobulin A nephropathy (IgAN).
  • Interim data from the JUNIPER trial are expected in 2027.
  • JADE101 is a fully human monoclonal antibody designed with ultra-high binding affinity to selectively block APRIL, a key driver of pathogenic IgA production.
  • Preclinical studies indicate JADE101 has a serum half-life of approximately 27 days \& supports subcutaneous dosing no more frequently than every eight weeks.
  • The open-label JUNIPER trial involves approximately 30 participants \& will evaluate safety, tolerability, urine protein-to-creatinine ratio changes, renal function, \& hematuria resolution.
  • IgAN affects approximately 169,000 people in the U.S., is often diagnosed in young adults, \& can lead to end-stage kidney disease.
  • Jade's pipeline also includes JADE201, an anti-BAFF-R monoclonal antibody, \& JADE301, an undisclosed antibody program.